WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

Firm News

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners. The deal is meant to help fund an oncology pipeline for Curis.

The WilmerHale deal team that represented Curis included John Sigel and Eric French.

For more information read Curis' Fourth Quarter and Year-End Financial Results press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.